A computer program is described which calculates suggested daily anticoagulant dose schedules for long term patients. This program is a part of the real-time Information System for Thrombosis Centres. The program requires only the most recent information on the patient from the Information System's
Computer-aided long-term anticoagulation therapy
β Scribed by Lewis B. Sheiner
- Publisher
- Elsevier Science
- Year
- 1969
- Tongue
- English
- Weight
- 807 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0010-4809
No coin nor oath required. For personal study only.
β¦ Synopsis
A computer program is described which calculates a suggested daily anticoagulant dose schedule for a patient. The program requires previous prothrombin times and drug dosages as well as physician determined therapeutic goals and limits. A simple compartmental response model is used to predict prothrombin time responses from previous drug doses. Suitable future dose suggestions are calculated from these prothrombin time predictions. A retrospective study provided a test of the program's performance relative to that of resident physicians and three staff cardiologists at a large teaching hospital. The doses computed by the program were found to compare favorably with those of the pilot sample of physicians.
π SIMILAR VOLUMES
Since 1969 the Massachusetts General Hospital has operated a centralized clinic to monitor outpatients taking oral anticoagulant drugs. The clinic was converted from handwritten records to an on-line computer system eally in 1972, and has since been able to serve a steadily increasing group of patie
## Abstract We analyze two donors providing longβ and shortβrun aid to one receiving (poor) country, and who may give aid in coordinated or nonβcoordinated fashion. An elite controls receiver policy, and diverts resources away from a poor target group. When strategic moves are simultaneous, there i
Rituximab, a chimeric monoclonal CD20 antibody, is useful in the treatment of B-cell lymphomas and certain autoimmune diseases. We report a successful outcome of rituximab for life threatening hypercoagulable state associated with lupus anticoagulant (LA). A 30-year-old woman initially presented 10